Table 3.
Variable description and Cox proportional regression analysis results for prediction of biochemical recurrence
| Characteristics pathologic BCR, N = 371 | BCR (n = 33) | No BCR (n = 338) | Univariate P value | Multivariate HR (95% CI) | P value |
|---|---|---|---|---|---|
| Median age at RARP, y (range) | 57 (46–73) | 60 (38–76) | 0.26 | ||
| Median pre-OP PSA, ng/ml (range) | 8.9 (0.6–46.0) | 5.5 (0.1–55.7) | 0.03 | 1.02 (0.99–1.05) | 0.31 |
| Clinical Stage, DRE (%) | |||||
| T1C | 24 (72.7) | 309 (91.4) | – | ||
| ≥T2A | 9 (27.3) | 29 (8.6) | 0.003 | 2.76 (1.21–6.31) | 0.02 |
| Race (%) | |||||
| White | 23 (74.2) | 245 (74.7) | – | ||
| Black | 5 (16.1) | 67 (20.4) | 0.43 | ||
| Other | 3 (9.7) | 16 (4.9) | 0.45 | ||
| Median MRI-TCL, mm (range) | 19.2 (0–53.2) | 11.2 (0–65.8) | 0.001 | 1.03 (1.01–1.06) | 0.02 |
| Biopsy GS distribution (%) | |||||
| GS sum 6 and 7 | 19 (57.6) | 279 (82.5) | – | ||
| GS sum ≥8 | 14 (42.4) | 59 (17.5) | <0.0001 | 3.29 (1.61–6.72) | 0.001 |
| Median MRI prostate volume cm3 (range) | 30.2 (20–93) | 37.0 (15–158) | 0.12 | ||
| MRI Suspicion score (%) | |||||
| Low and low-moderate | 0(0) | 46 (13.6) | – | ||
| Moderate | 9 (27.3) | 180 (53.4) | 0.90 | ||
| Moderate-high and high | 24 (72.7) | 111 (32.9) | 0.89 | ||
DRE = digital rectal examination; RARP = robotic-assisted radical prostatectomy.